MIR342

Summary

MIR342 (microRNA 342, HGNC:31778) is a microRNA gene on chromosome 14q32.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 442909 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31778
Approved symbol	MIR342
Name	microRNA 342
Location	14q32.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-342
Ensembl gene	ENSG00000199082
Ensembl biotype	miRNA
Entrez	442909
RNAcentral	URS000071B780 — miRNA, 99 nt, 20 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000362212

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000362212 — 1 exons

Exon	Start	End
ENSE00001436975	100109655	100109753

Expression profiles

Bgee: expression breadth broad, 62 present calls, max score 89.18.

Top tissues by expression

62 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	89.18	gold quality
sural nerve	UBERON:0015488	89.16	gold quality
bone marrow	UBERON:0002371	82.96	gold quality
liver	UBERON:0002107	79.91	gold quality
blood	UBERON:0000178	78.24	gold quality
monocyte	CL:0000576	76.82	gold quality
right adrenal gland	UBERON:0001233	76.39	gold quality
lymph node	UBERON:0000029	74.78	gold quality
placenta	UBERON:0001987	73.26	gold quality
heart left ventricle	UBERON:0002084	72.84	gold quality
gastrocnemius	UBERON:0001388	71.47	gold quality
stomach	UBERON:0000945	70.83	gold quality
body of stomach	UBERON:0001161	70.66	gold quality
Brodmann (1909) area 9	UBERON:0013540	70.28	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	70.16	gold quality
ascending aorta	UBERON:0001496	70.11	gold quality
islet of Langerhans	UBERON:0000006	69.78	gold quality
thoracic aorta	UBERON:0001515	69.42	gold quality
skin of abdomen	UBERON:0001416	69.32	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	68.82	gold quality
zone of skin	UBERON:0000014	68.43	gold quality
myometrium	UBERON:0001296	68.07	gold quality
heart	UBERON:0000948	67.98	gold quality
skin of leg	UBERON:0001511	67.95	gold quality
left adrenal gland	UBERON:0001234	67.87	gold quality
esophagus mucosa	UBERON:0002469	67.80	gold quality
left ovary	UBERON:0002119	67.60	gold quality
omental fat pad	UBERON:0010414	67.56	gold quality
muscle layer of sigmoid colon	UBERON:0035805	67.55	gold quality
endometrium	UBERON:0001295	67.44	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.51

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): IRF1, IRF9, SPI1

Literature-anchored findings (GeneRIF, showing 40)

• Data show significantly increased expression of miRNA-510 and decreased expression of both miRNA-342 and miRNA-191 in Tregs of diabetic patients. (PMID:19954774)
• Down-regulation of intronically encoded miR-342 plays a role in the pathogenesis of Sezary syndrome by inhibiting apoptosis via binding of miR-199a. (PMID:20448109)
• Results suggest that miR-342 regulates expression of genes involved in tamoxifen mediated tumor cell apoptosis and cell cycle progression. (PMID:21172025)
• Results showed that overexpression of miR-342 significantly inhibited tumor growth and lung metastasis in nude mice (PMID:21565830)
• MiR-342-5p suppresses coxsackievirus B3 biosynthesis by targeting the 2C-coding region. (PMID:22197249)
• expression of MiR-21, MiR-205, and MiR-342 was analyzed in ER-positive and/or PR-positive group (group I); HER2-positive group (group II); and ER/PR/HER2- negative (group III) breast cancer; expression of miR-21 was similar in all 3 groups; miR-205 and miR-342 expression were down regulated in group III (PMID:22631664)
• miR-185 and 342 control lipogenesis and cholesterogenesis in prostate cancer cells by inhibiting SREBP-1 and 2 expression and downregulating their targeted genes, FASN and HMGCR. (PMID:23951060)
• miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer (PMID:24475217)
• hsa-miR-150 and hsa-miR-342-3p were identified as up-regulated in irritable bowel syndrome patients compared to healthy controls. (PMID:24768587)
• FOXM1 is upregulated and negatively correlates with miR-342-3p in cervical cancer tissues (PMID:25066298)
• After confirming overexpression of miR-342-3p, hepatocellular carcinoma cell proliferation was significantly inhibited by miR-342-3p, decreasing cell proliferation by nearly sixfold. (PMID:25580008)
• Our collective findings provide preliminary evidence that miR-342-3p acts as a tumor suppressor in -small cell lung cancer through repression of RAP2B. (PMID:25663460)
• High MIR342 expression is associated with thyroid papillary carcinoma. (PMID:25908172)
• MIR342-3p was differentially expressed in obese children with and without endothelial dysfunction. (PMID:26270249)
• miR-342-3p is capable of indirectly regulating MYC activity via direct repression of E2F1. (PMID:26483346)
• The results implicate miR-342-5p and miR-608 in colon cancer development and unveil the underlying mechanism of this phenomenon, which involves NAA10. (PMID:26646451)
• miR-342-5p acts as a multifunctional angiogenic repressor mediating the effects and interaction among angiogenic Notch1/VEGF/TGF-beta signaling pathways. (PMID:26857067)
• Findings suggest a tumor-suppressive function of miR-342 in breast neoplasms. (PMID:26919240)
• We identified FOXM1 and FOXQ1 as novel prognostic biomarkers in colorectal cancer and miR-342 as a novel regulator of both FOXM1 and FOXQ1 (PMID:27162244)
• These findings suggest that enhanced miR-342-3p expression is a component of a negative feedback loop controlling excessive macrophage proliferation during Th2-type inflammatory responses. Moreover, study indicates that miR-342-3p likely plays a pro-apoptotic role in such cells, thereby providing a negative feedback arm to IL-4-dependent macrophage proliferation. (PMID:27245778)
• the regulation of lumen formation by miR-342 involves at least two of its known targets, namely ID4 and DNMT1. (PMID:27302063)
• exosomal miR-133b, miR-342, and miR-30a were expressed at significantly elevated levels in Type 2 diabetic nephropathy patients (P<0.001) compared to normal. (PMID:27470555)
• Results found that MIR342 was down-regulated in gallbladder cancer (GBC) tissues and identified H19 as its direct target. (PMID:27716361)
• Long noncoding RNA FTX regulated astrocyte-elevated gene-1 (AEG-1) expression through microRNA miR-342-3p. (PMID:28112756)
• Results show that miR-342-3p inhibits the proliferation, migration, and invasion of osteosarcoma cells through targeting AEG-1. (PMID:28276315)
• 342-3p expression was significantly decreased in hepatocellular carcinoma tissues compared with paired adjacent non-tumor tissues; MiR-342-3p expression was correlated with histologic grade and tumor TNM stage (PMID:28537676)
• Low miR342 expression is associated with glioma. (PMID:28677773)
• In conclusion, this study showed the potential of miR-342-3p as a therapeutic target to promote bone regeneration by modulating expression of Sufu in UCMSCs. (PMID:28765042)
• AGR2 expression is up-regulated and negatively correlated with miR-342-3p levels in NSCLC cells and tissues. (PMID:29107102)
• EVL/miR-342 methylation was preferentially detected in IgD multiple myeloma (PMID:29242101)
• Novel circulating miRNAs mirn214 and mirn342 were upregulated in the serum of Atrial Fibrillation patients and might be potential biomarkers of AF. (PMID:29398686)
• The network model simulations and experimental data indicate the ability of enhanced expression of both miR-205-5p and miR-342-3p to decrease tumor chemoresistance by cooperatively repressing E2F1. (PMID:29464002)
• restoring the function of Runx2-targeting by miR-342 and miR-363 in multiple myeloma cells may afford a therapeutic benefit by preventing multiple myeloma progression.Implications: miR-342 and miR-363-mediated downregulation of Runx2 expression in multiple myeloma cells prevents multiple myeloma progression (PMID:29592898)
• endothelial miR-342-3p expression was significantly compromised in T2DM organisms and this inhibition powerfully blocked vasculogenesis in vivo by repressing endothelial proliferation and migration. From a mechanistic standpoint, miR-342-3p promoted the transactivation of fibroblast growth factor 11 (FGF11) by directly targeting its 3’ untranslated regions (3’UTRs). (PMID:29852165)
• Study revealed that miR3423p levels were significantly inversely correlated with the protein levels of its target CDC42 in nasopharyngeal carcinoma (NPC) tissues. Overexpression of miR-342-3p inhibited NPC cell proliferation and invasion by directly targeting CDC42. (PMID:30106159)
• Loss of function of miR-342-3p results in MCT1 over-expression and contributes to oncogenic metabolic reprogramming in triple negative breast cancer (PMID:30115973)
• Data show that miR-342-3p directly targets activating transcription factor 3 (ATF3), which inhibits transcription of pro-osteogenic differentiation-associated genes. (PMID:30381822)
• our results reveal a novel pathway that SCARNA2 regulates colorectal cancer chemoresistance through targeting miR-342-3p-EGFR/BCL2 pathway (PMID:30443961)
• The data suggest that miR-342-5p overexpression in HER2 positive Breast Cancer cell lines elicits broad effects on HER2 downstream signaling, cell motility and mitochondrial stability. (PMID:30520388)
• miR-342-3p expression is up-regulated in gemcitabine (GEM)-resistant pancreatic ductal adenocarcinoma. Crosstalk between leptin and Notch pathways regulates the miR-342-3p expression. (PMID:30638935)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir342	ENSMUSG00000065436
rattus_norvegicus	Mir342	ENSRNOG00000035612

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.